G
Gefei Guan
Researcher at China Medical University (PRC)
Publications - 23
Citations - 414
Gefei Guan is an academic researcher from China Medical University (PRC). The author has contributed to research in topics: Glioma & Immunotherapy. The author has an hindex of 9, co-authored 19 publications receiving 175 citations.
Papers
More filters
Journal ArticleDOI
A risk signature with four autophagy‐related genes for predicting survival of glioblastoma multiforme
TL;DR: The risk signature with 4 autophagy‐related genes could serve as an independent prognostic factor for GBM patients and was developed based on the risk signature and clinical traits which was validated to perform better for predicting 1‐, 3‐ and 5‐year survival rate of GBM.
Journal ArticleDOI
Long non-coding RNA, HOTAIRM1, promotes glioma malignancy by forming a ceRNA network.
TL;DR: RNA sequencing data for 946 glioma samples were analyzed and it was suggested that HOTAIRM1 is a prognostic biomarker and potential therapeutic target in gliomas.
Journal ArticleDOI
Ferroptosis, as the most enriched programmed cell death process in glioma, induces immunosuppression and immunotherapy resistance.
Tianqi Liu,Chen Zhu,Xin Chen,Gefei Guan,Cunyi Zou,Shuai Shen,Jianqi Wu,Yuhang Wang,Zhiguo Lin,Ling Chen,Peng Cheng,Wen-Chun Cheng,Anhua Wu +12 more
TL;DR: A role of ferroptosis in glioma malignancy and a novel synergic immunotherapeutic strategy that combines immune checkpoint blockade (ICB) treatment with ferroPTosis inhibition are suggested.
Journal ArticleDOI
Development and validation of an interferon signature predicting prognosis and treatment response for glioblastoma.
Chen Zhu,Cunyi Zou,Gefei Guan,Qing Guo,Zihao Yan,Tianqi Liu,Shuai Shen,Xiaoyan Xu,Chen Chen,Zhiguo Lin,Wen Cheng,Anhua Wu +11 more
TL;DR: ThisInterferon signature was an independent indicator for unfavorable prognosis and showed great potential for screening out patients who will benefit from chemotherapy and interferon treatment.
Journal ArticleDOI
ARL2 overexpression inhibits glioma proliferation and tumorigenicity via down-regulating AXL
TL;DR: This study suggests that ARL2 inhibits the proliferation, migration and tumorigenicity of glioma cells by regulating the expression of AXL and may conduct as a new prognostic and therapeutic target forglioma.